FinnCap restated their corporate rating on shares of Avacta Group Plc (LON:AVCT) in a research report sent to investors on Tuesday morning. They currently have a GBX 200 ($2.63) target price on the biotechnology company’s stock.
Avacta Group Plc (AVCT) opened at 72.00 on Tuesday. Avacta Group Plc has a one year low of GBX 60.00 and a one year high of GBX 98.00. The stock has a 50 day moving average price of GBX 72.85 and a 200-day moving average price of GBX 80.21. The stock’s market cap is GBX 49.24 million.
In related news, insider Alastair Smith purchased 33,225 shares of the company’s stock in a transaction dated Monday, August 21st. The stock was acquired at an average cost of GBX 75 ($0.99) per share, for a total transaction of £24,918.75 ($32,761.96).
About Avacta Group Plc
Avacta Group plc is a biotechnology company. Avacta’s focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies.
Receive News & Ratings for Avacta Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group Plc and related companies with MarketBeat.com's FREE daily email newsletter.